Author: Ken Dropiewski

Final Patient Dosed in Mesoblast Phase 3 Trial of Revascor Cell Therapy for Advanced Heart Failure

NEW YORK and MELBOURNE, Australia, Feb. 19, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a world leader in development and commercialization of cellular medicines, announced today that the last patient has now been dosed in the Phase 3 events-driven trial of its allogeneic cell therapy product candidate Revascor for advanced chronic […]

Hancock Jaffe Successfully Starts First-in-Human VenoValve Study

IRVINE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced the successful start of its VenoValve® first-in-human study in Bogota, Colombia. The first VenoValve was implanted in a patient and the procedure […]

Philips launches Zenition mobile C-arm platform for enhanced operating room performance and workflow efficiency

AMSTERDAM, Feb. 18, 2019 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Zenition, its new mobile C-arm imaging platform. Mobile C-arms are X-ray systems that are brought into the operating room (OR) to provide live image guidance during a wide range of surgeries including […]

Affluent Medical Releases Impressive Results from Scope 1 Clinical Trial Validating Efficacy of KARDIOZIS Technology

PARIS–(BUSINESS WIRE)–Affluent Medical (Paris:ALAM), a French medtech company specialized in innovative, minimally invasive implants designed to restore key physiological functions for patients suffering from heart and vascular diseases, as well as urinary incontinence, today announces positive results from its SCOPE 1 clinical trial validating the efficacy of KARDIOZIS technology. Results have been […]

Foldax, Inc. Gains Approval to Begin US Clinical Trials of the First and Only Biopolymer Heart Valve Platform

SALT LAKE CITY–(BUSINESS WIRE)–Foldax, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval to begin an Early Feasibility Study of the Tria surgical aortic heart valve for the treatment of aortic valve disease. Using breakthrough LifePolymer™ – a proprietary advanced biopolymer material – and […]

Caladrius Biosciences Reports Top-Line Data for the Phase 2a Sanford Project: T-Rex Trial of CLBS03 for Recent Onset Type 1 Diabetes

BASKING RIDGE, N.J., Feb. 13, 2019 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple development programs targeting select cardiovascular indications and autoimmune disease, today announced  top-line results from The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind Phase […]

Semler to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on February 27, 2019

SAN JOSE, Calif., Feb. 14, 2019 /PRNewswire/ — Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for fourth quarter and full year ended December 31, 2018 before the open of U.S. […]

Medicure Provides Update on Release of Holdback Funds from Apicore Sale

WINNIPEG, Feb. 13, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV:MPH,OTC: MCUJF), a cardiovascular pharmaceutical company, today announced that it has received notice from the purchaser of Medicure’s interests in Apicore of potential claims against funds held back in respect of representations and warranties under the Apicore sale agreement. The notice does […]